Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
AntlerA Therapeutics Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This pending matter is assigned to 1 distinct examiner working within 1 distinct art unit. The concentration of the portfolio suggests a highly focused prosecution strategy at this stage of the company's patent development. Practitioners should note that the entire active docket is confined to a specific administrative path within the USPTO.
The busiest examiner for the company is XIAO, YAN, who is responsible for 1 busiest examiner pending action. Because the total number of 1 pending office action is assigned to this individual, the examiner handles the entirety of the company's current workload. This alignment between the total volume and the individual examiner's load indicates a lack of diversification across different USPTO personnel. The company must tailor its arguments specifically to the preferences of XIAO, YAN. Success in the Biotechnology & Pharmaceuticals sector for this portfolio depends on successfully navigating the specific requirements of the assigned personnel. Future filings may eventually expand the footprint beyond the current examiner and 1 distinct art unit, but current efforts remain centralized.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| XIAO, YAN | 1 | 67.3% | +52.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial